On November 15, 2014, Yin, Kai-Hao; Hsieh, Yi-Han; Sulake, Rohidas S.; Wang, Su-Pei; Chao, Jui-I.; Chen, Chinpiao published an article.SDS of cas: 35444-44-1 The title of the article was Optimization of gefitinib analogues with potent anticancer activity. And the article contained the following:
The interactions of gefitinib (Iressa) in epidermal growth factor receptor (EGFR) are hydrogen bonding and van der Waals forces through quinazoline and aniline rings. However the morpholino group of gefitinib is poorly ordered due to its weak electron d. A series of novel piperazino analogs of gefitinib where morpholino groups substituted with various piperazino groups were designed and synthesized. Most of them indicated significant anti-cancer activities against human cancer cell lines. In particular, three compounds alkyl 4-(4-(3-(4-(3-chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)propyl)piperazin-1-yl)-4-oxobutanoate (alkyl = decyl, undecyl, dodecyl) showed excellent potency against cancer cells. Convergent synthetic approach has been developed for the synthesis of gefitinib intermediate which can lead to gefitinib as well as numerous analogs. The experimental process involved the reaction of Methyl 6-chloro-6-oxohexanoate(cas: 35444-44-1).SDS of cas: 35444-44-1
The Article related to piperazino analog gefitinib anticancer activity, quinazolinyloxypropylpiperazinylbutanoate preparation anticancer activity, a549, anti-cancer, egfr, gefitinib, iressa, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.SDS of cas: 35444-44-1
Referemce:
Chloride – Wikipedia,
Chlorides – an overview | ScienceDirect Topics